Key terms
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TBPH news
Apr 12
7:11am ET
Theravance Biopharma initiated with a Buy at BTIG
Mar 06
11:16pm ET
Analyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment Potential
Mar 03
1:00am ET
A New Cause for Concern: Theravance Biopharma Adds a New Costs Risk
Mar 02
11:30am ET
Short Report: Bears cut down exposure to crypto names as bitcoin price spikes
Feb 27
11:39pm ET
Theravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestones
Feb 27
6:27am ET
Theravance Biopharma: A Strong Buy on Robust Yupelri Sales and Promising Financial Milestones
Feb 26
9:55pm ET
Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma
Feb 26
4:08pm ET
Theravance Biopharma reports Q4 EPS (17c), consensus (15c)
No recent press releases are available for TBPH
TBPH Financials
Key terms
Ad Feedback
TBPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TBPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
